Collegium Pharmaceutical (COLL) Change in Receivables (2016 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Change in Receivables of $17.4 million for Q1 2026, up 10155.29% year-over-year from N/an in Q1 2025, and up 177.07% quarter-over-quarter from -$22.6 million in Q4 2025.
Collegium Pharmaceutical (COLL) Change in Receivables (2016 - 2026) Analysis & Trends
Collegium Pharmaceutical's Change in Receivables history runs 11 years deep, the most recent figure standing at $17.4 million for Q1 2026.
- In Q1 2026, Change in Receivables rose 10155.29% year-over-year to $17.4 million; the TTM figure through Mar 2026 stood at $60000.0 (down 99.36% YoY), while the FY2025 annual figure was -$17.2 million, down 489.76% from the prior year.
- Change in Receivables for Q1 2026 stood at $17.4 million, up from -$22.6 million in the prior quarter.
- The five-year high for Change in Receivables was $31.2 million in Q2 2022, with the low at -$22.6 million in Q4 2025.
- The 5-year median for Change in Receivables is -$106000.0 (2024), against an average of $1.3 million.
- Peak annual rise in Change in Receivables reached 10913.68% in 2025, while the deepest fall reached 21240.57% in 2025.
- Collegium Pharmaceutical's Change in Receivables stood at -$12.3 million in 2022, then soared by 81.06% to -$2.3 million in 2023, then surged by 95.44% to -$106000.0 in 2024, then tumbled by 21240.57% to -$22.6 million in 2025, then soared by 177.07% to $17.4 million in 2026.
- Business Quant data shows COLL's Change in Receivables at $17.4 million in Q1 2026, -$22.6 million in Q4 2025, and $20.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Collegium Pharmaceutical | 897.54 Mn | 748.22 Mn | 110.29 Mn | -2.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.13 Mn |
| Jun 30, 2026 | -2.13 Mn |
| Mar 31, 2026 | 17.43 Mn |
| Mar 31, 2026 | 17.43 Mn |
| Dec 31, 2025 | -22.62 Mn |
| Dec 31, 2025 | -22.62 Mn |
| Sep 30, 2025 | 20.93 Mn |
| Sep 30, 2025 | 20.93 Mn |
| Jun 30, 2025 | -15.68 Mn |
| Jun 30, 2025 | -15.68 Mn |
| Mar 31, 2025 | 170,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Dec 31, 2024 | -106,000.00 |
| Dec 31, 2024 | -106,000.00 |
| Sep 30, 2024 | 190,000.00 |
| Sep 30, 2024 | 190,000.00 |
| Jun 30, 2024 | 9.16 Mn |
| Jun 30, 2024 | 9.16 Mn |
| Mar 31, 2024 | -4.83 Mn |
| Mar 31, 2024 | -4.83 Mn |